Okay, let's tackle this question. The patient is a 40-year-old male with splenomegaly, sternal tenderness, and a very high WBC count—85,000 with myelocytes and metamyelocytes. Hmm, that sounds like a myeloproliferative disorder. The key here is to figure out which specific condition and the appropriate treatment.

First, the core concept would be chronic myeloid leukemia (CML), especially the accelerated or blast crisis phase. The presence of immature myeloid cells (myelocytes, metamyelocytes) in the peripheral blood is a classic sign. Splenomegaly and sternal tenderness are common due to leukemic infiltration and marrow expansion.

Looking at the options, the correct answer is likely a tyrosine kinase inhibitor like imatinib. CML is driven by the Philadelphia chromosome, which creates the BCR-ABL fusion protein. Tyrosine kinase inhibitors target this protein, making them the first-line treatment.

Now, the wrong options might include other drugs. Let's say Option A is hydroxyurea. That's used for CML in blast crisis but not the first-line. Option B could be a corticosteroid, which isn't effective here. Option C might be a chemotherapeutic agent like vincristine, which isn't the primary treatment. Option D could be a different TKI like dasatinib, but if the question is about the best initial drug, imatinib would be the answer.

The clinical pearl here is that in CML, especially chronic phase, tyrosine kinase inhibitors are the mainstay, not just any cytoreductive agent. Also, high WBC with immature cells in peripheral blood is a red flag for blast crisis, which requires urgent management.

**Core Concept**
This case highlights **chronic myeloid leukemia (CML)** in the **blast crisis phase**, characterized by marked leukocytosis with immature myeloid cells (myelocytes/metamyelocytes), splenomegaly, and sternal tenderness. The Philadelphia chromosome (t(9;22)) and BCR-ABL fusion protein drive the disease, making tyrosine kinase inhibitors (TKIs) the cornerstone of treatment.

**Why the Correct Answer is Right**
**Imatinib (a tyrosine kinase inhibitor)** is the first-line therapy for CML, including blast crisis. It inhibits the BCR-ABL tyrosine kinase enzyme, blocking the uncontrolled proliferation of leukemic myeloid blasts. This reduces peripheral blood blast counts, controls splenomegaly, and induces remission. Other cytoreductive agents like hydroxyurea may temporarily lower WBC but do not target the underlying pathogenesis.

**Why Each Wrong Option is Incorrect**
**Option A: Hydroxyurea** – A myelosuppressive agent used for rapid cytoreduction in CML, but it lacks specificity for BCR-ABL and is not curative.
**Option B: Corticosteroids** – Ineffective in CML; reserved for hypereosinophilic syndromes or steroid-responsive leukemias.
**Option C: Vincristine** – A chemotherapy agent used in acute leukemias, but not first-line for CML due to poor efficacy against BCR

✓ Correct Answer: D. Hydroxyurea